Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Legend Biotech Corp
LEGN | US
35.98
USD-0.30
-0.83%
LEGN | US
About Legend Biotech Corp
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
03/06/2026
Close
35.98
Open
34.98
High
37.45
Low
34.35
Legend Biotech Corporation a clinical-stage biopharmaceutical company through its subsidiaries engages in the discovery development manufacturing and commercialization of novel cell therapies for oncology and other indications in the United States China and internationally. Its lead product candidate LCAR- B38M is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers including Non-Hodgkins Lymphoma acute lymphoblastic leukemia gastric cancer esophageal cancer pancreatic cancer colorectal cancer hepatocellular carcinoma small cell lung cancer and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
View LessLEGN | US
Risk
162.4
Sharpe
0.26
Luna's Score
54/100
Recommendation
Hold
Luna says (LEGN | US)
What's Working
Positive Momentum
Low Market Beta (-0.4 to 0.8)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
What's not Working
Weakness based on declining price with high volume
High Short-term Volatility
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
221.9%1 month
162.4%3 months
109.9%6 months
89.1%Returns
Fundamental Ratios
PE
-
Fwd. PE
357.14
Price to book
6.85
Debt to equity
0.29
Debt to assets
0.19
Ent. to EBITDA
-15.34
Ent. to rev.
15.32
PEG
-
Other Fundamentals
EBITDA
-362.43M
MarketCap
6.63B
MarketCap(USD)
6.63B
Div. yield
-
Op. margin
-22.50
Erngs. growth
-
Rev. growth
154.40
Ret. on equity
-22.21
Short ratio
12.36
Short perc.
12.46
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
12.64
Range1M
13.88
Range3M
20.75
Volumes: Market Activity
Rel. volume
1.29
Price X volume
146.85M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -15.34 | - | Cheaper |
| Ent. to Revenue | 15.32 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 6.85 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 109.87 | - | Riskier |
| Debt to Equity | 0.29 | -1.23 | Expensive |
| Debt to Assets | 0.19 | 0.25 | Cheaper |
| Market Cap | 6.63B | - | Market Leader |
